Trials / Completed
CompletedNCT07294586
Exploratory Clinical Study and Validation of Blood Biomarkers for Alzheimer's Disease
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 200 (actual)
- Sponsor
- Amoneta Diagnostics SAS · Industry
- Sex
- All
- Age
- 50 Years – 85 Years
- Healthy volunteers
- Accepted
Summary
This is a 24-month, monocentric, exploratory and observational clinical study aimed at developing and validating a blood-based diagnostic test for Alzheimer's disease (AD). The test is based on two complementary biomarkers: conformational changes in Protein Kinase C (PKC) and aggregation of β-amyloid peptide on red blood cell membranes. The study will also establish a biobank of serum, plasma, urine, and RNA samples for future biomarker research.
Conditions
- Alzheimer Disease
- Dementia
- Neurodegenerative Disorders
- Cognitive Decline
- Memory Loss
- Mild Cognitive Impairment (MCI)
- Early Onset Alzheimer Disease
- Late Onset Alzheimer Disease
Timeline
- Start date
- 2019-10-28
- Primary completion
- 2019-10-28
- Completion
- 2021-06-24
- First posted
- 2025-12-19
- Last updated
- 2025-12-19
Locations
1 site across 1 country: France
Source: ClinicalTrials.gov record NCT07294586. Inclusion in this directory is not an endorsement.